Application of neo-bioscore staging to predict the benefit of pertuzumab in HER2 positive early breast cancer

被引：0
|
作者：
Sanchez Escudero, L. [1 ]
Morales Pancorbo, D. [2 ]
Bayo, J. [3 ]
Aragon Manrique, I. [3 ]
机构：
[1] Hosp Juan Ramon Jimenez, Oncol, Huelva, Spain
[2] Hosp Juan Ramon Jimenez, Med, Huelva, Spain
[3] Hosp Juan Ramon Jimenez, Oncol Med, Huelva, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
197P
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [31] Evaluation of the relationship between Ki67 expression level and neoadjuvant treatment response and prognosis in breast cancer based on the Neo-Bioscore staging system
    Sullu Y.
    Tomak L.
    Demirag G.
    Kuru B.
    Ozen N.
    Karagoz F.
    Discover Oncology, 14 (1)
  • [32] IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER
    Vaidya, T. R.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S20
  • [33] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [34] BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
    Liefaard, M. C.
    van der Voort, A.
    van Ramshorst, M. S.
    Sanders, J.
    Vonk, S.
    Horlings, H. M.
    Siesling, S.
    de Munck, L.
    van Leeuwen, A. E.
    Kleijn, M.
    Mittempergher, L.
    Kuilman, M. M.
    Glas, A. M.
    Wesseling, J.
    Lips, E. H.
    Sonke, G. S.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [35] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [36] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [37] BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
    M. C. Liefaard
    A. van der Voort
    M. S. van Ramshorst
    J. Sanders
    S. Vonk
    H. M. Horlings
    S. Siesling
    L. de Munck
    A. E. van Leeuwen
    M. Kleijn
    L. Mittempergher
    M. M. Kuilman
    A. M. Glas
    J. Wesseling
    E. H. Lips
    G. S. Sonke
    Breast Cancer Research, 25
  • [38] Prognostic value of residual cancer burden (RCB), neo-bioscore and neoadjuvant response index (NRI) to evaluate response to neoadjuvant trastuzumab-based therapy in HER2-positive breast cancer (BC)
    Steenbruggen, T. G.
    van Seijen, M.
    Janssen, L. M.
    van Ramshorst, M. S.
    van Werkhoven, E.
    Lips, E. H.
    Vrancken-Peeters, M-JT
    Horlings, H. M.
    Wesseling, J.
    Sonke, G. S.
    CANCER RESEARCH, 2019, 79 (04)
  • [39] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
12345